Medtronic reported Q results with revenue of 9.81 billion, beating consensus of 9.73 billion, and EPS of 1.55 versus the 1.56 estimate, driven by 6.6 percent organic growth in the quarter and a record 5.8 percent for the full year, its strongest in a decade. Growth was concentrated in high-potential platforms, including 78 percent expansion in Cardiac Ablation Solutions with pulsed-field ablation up 145 percent and now annualizing above 2 billion, plus Symplicity renal denervation reaching a 100 million annualized run rate. Following the diabetes spin-off and tuck-in acquisitions, management positioned the portfolio for sustained compounding through an integrated electrophysiology ecosystem and Hugo robotics submission, though sustainability amid macro pressures and competition remains a key question.

Company: Medtronic plc (MDT) — Q4 FY202 ...